The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation

Vaccine

Volumn 17, Issue 7-8, 1999, Pages 893-903

  Kalus, R M ^a   Kantor, J A ^b   Gritz, L ^c   Yafal, A Gómez ^c   Mazzara, G P ^c   Schlom, J ^b   Hodge, J W ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Therion Biologics Corporation   (United States)

Author keywords

Antitumor; B7.1; CEA; Combination vaccine; Dual gene vaccine; Vaccinia

Indexed keywords

B7 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR ANTIGEN; TUMOR VACCINE;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN SCAR; T LYMPHOCYTE; TRANSGENE; VACCINIA VIRUS; VIRUS RECOMBINANT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD80; CARCINOEMBRYONIC ANTIGEN; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNITY, CELLULAR; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES; TRANSGENES; VACCINES, COMBINED; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0033605240     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00275-8     Document Type: Article

References (41)

1. McAneny D., Ryan C.A., Beazley R.M., Kaufman H.L. Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol. 3:1996;495-500.
2. Tsang K.Y., Zaremba S., Nieroda C.A., Zhu M.Z., Hamilton J.M., Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst. 87:1995;982-990.
3. Hodge J.W. Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol Immunother. 43:1996;127-134.
4. Hamilton J.M., Chen A.P., Nguyen B., Gram J., Abrams S., Chung Y., Kantor J., Phares J.C., Bastian A., Brooks C., Morrison G., Allegra C.J., Schlom J. Phase 1 study of recombinant vaccinia virus (rV) that expresses human carcinoembryonic antigen (CEA) in adult patients with adenocarcinomas. ASCO Proc. 961:1994.
5. Hodge J.W., Schlom J., Donohue S.J., Tomaszewski J.E., Wheeler C.W., Levine B.S., Gritz L., Panicali D., Kantor J.A. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer. 63:1995;231-237.
6. Borysiewicz L.K., Fiander A., Nimako M., Man S., Wilkinson G.W., Westmoreland D., Evans A.S., Adams M., Stacey S.N., Boursnell M.E., Rutherford E., Hickling J.K., Inglis S.C. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 347:1996;1523-1527.
7. Achour A., Bex F., Hermans P., Burny A., Zagury D. Induction of anti-gp160 cytotoxic T cells cross-reacting with various V3 loop P18 peptides in human immunodeficiency virus type 1 envelope-immunized individuals. J Virol. 70:1996;6741-6750.
8. Kim J.J., Ayyavoo V., Bagarazzi M.L., Chattergoon M., Boyer J.D., Wang B., Weiner D.B. Development of a multicomponent candidate vaccine for HIV-1. Vaccine. 15:1997;879-883.
9. Perales M.A., Schwartz D.H., Fabry J.A., Lieberman J. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. J Acquir Immune Defic Syndr Hum Retrovirol. 10:1995;27-35.
10. Zhai Y., Yang J.C., Spiess P., Nishimura M.I., Overwijk W.W., Roberts B., Restifo N.P., Rosenberg S.A. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother. 20:1997;15-25.
11. Kittlesen D.J., Thompson L.W., Gulden P.H., Skipper J.C., Colella T.A., Shabanowitz J.A., Hunt D.F., Engelhard V.H., Slingluff C.L. Jr. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. J Immunol. 160:1998;2099-2106.
12. Tine J.A., Lanar D.E., Smith D.M., Wellde B.T., Schultheiss P., Ware L.A., Kauffman E.B., Wirtz R.A., De Taisne C., Hui G.S., Chang S.P., Church P., Hollingdale M.R., Kaslow D.C., Hoffman S., Guito K.P., Ballou W.R., Sadoff J.C., Paoletti E. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun. 64:1996;3833-3844.
13. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A. 93:1996;11349-11353.
14. Perkus M.E., Tartaglia J., Paoletti E. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukoc Biol. 58:1995;1-13.
15. Cooney E.L., McElrath M.J., Corey L., Hu S., Collier A.C., Arditti D., Hoffman M., Coombs R.W., Smith G.E., Greenberg P.D. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proceedings of the National Academy of Science. 90:1993;1882-1886.
16. Etlinger H.M., Altenburger W. Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus. Vaccine. 9:1991;470-472.
17. Kundig T.M., Kalberer C.P, Hengartner H., Zinkernagel R.M. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine. 11:1993;1154-1158.
18. Fenner F., Henderson D.A., Arita I., Jezek Z., Ladnyi I.D. Smallpox and its erradication. Geneva: WHO, 1988. p. 1263-1270.
19. Hodge J.W., McLaughlin J.P., Kantor J.A., Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine. 15:1997;759-768.
20. Harding F.A., Allison J.P. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med. 177:1993;1791-1796.
21. Schultze J., Nadler L.M., Gribben J.G. B7-mediated costimulation and the immune response. Blood Rev. 10:1996;111-127.
22. Iwasaki A., Stiernholm B.J., Chan A.K., Berinstein N.L., Barber B.H. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol. 158:1997;4591-4601.
23. Conry R.M., Widera G., LoBuglio A.F., Fuller J.T., Moore S.E., Barlow D.L., Turner J., Yang N-S., Curiel D.T. Selected strategies to augment polynucleotide immunization. Gene Therapy. 3:1996;67-74.
24. Kim J.J., Bagarazzi M.L., Trivedi N., Hu Y., Kazahaya K., Wilson D.M., Ciccarelli R., Chattergoon M.A., Dang K., Mahalingam S., Chalian A.A., Agadjanyan M.G., Boyer J.D., Wang B., Weiner D.B. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol. 1997, 15. 641-646.
25. Chen L., McGowan P., Ashe S., Johnston J.V., Hellstrom I., Hellstrom K.E. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res. 54:1994;5420-5423.
26. Chen L. Manipulation of T cell response to tumors by targeting on costimulatory pathway. Leukemia. 11:(Suppl 3):1997;567-569.
27. Heuer J.G., Tucker-McClung C., Gonin R., Hock R.A. Retrovirus-mediated gene transfer of B7-1 and MHC class II converts a poorly immunogenic neuroblastoma into a highly immunogenic one. Hum Gene Ther. 7:1996;2059-2068.
28. Hodge J.W., Abrams S., Schlom J., Kantor J.A. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res. 54:1994;5552-5555.
29. Uzendoski K., Kantor J.A., Abrams S.I., Schlom J., Hodge J.W. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses. Hum Gene Ther. 8:1997;851-860.
30. Hodge J.W., McLaughlin J.P., Abrams S.I., Shupert W.L., Schlom J., Kantor J.A. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res. 55:1995;3598-3603.
31. Akagi J., Hodge J.W., McLaughlin J.P., Gritz L., Mazzara G., Kufe D., Schlom J., Kantor J.A. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. J Immunother. 20:1997;38-47.
32. Chamberlain R.S., Carroll M.W., Bronte V., Hwu P., Warren S., Yang J.C., Nishimura M., Moss B., Rosenberg S.A., Restifo N.P. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res. 56:1996;2832-2836.
33. Kaufman H., Schlom J., Kantor J. A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int J Cancer. 48:1991;900-907.
34. Gritz L., Destree A., Cormier N., Day E., Stallard V., Caiazzo T., Mazzara G., Panicali D. Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. J Virol. 64:1990;5948-5957.
35. Chakrabarti S., Sisler J.R., Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques. 23:1997;1094-1097.
36. Muraro R., Wunderlich D., Thor A., Lundy J., Noguchi P., Cunningham R., Schlom J. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Research. 45:1985;5769-5775.
37. Mazzara G.P., Destree A., Mahr A. Generation and analysis of vaccinia virus recombinants. Methods Enzymol. 217:1993;557-581.
38. Smith K.A., Stallard V., Roos J.M., Hart C., Cormier N., Cohen L.K., Roberts B.E., Payne L.G. Host range selection of vaccinia recombinants containing insertions of foreign genes into non-coding sequences. Vaccine. 11:1993;43-53.
39. Wunderlich J., Shearer G. Induction and measurement of cytotoxic T lymphocyte activity. In: Colligan J., KD , MD , SE , Strober W., editors. Current Protocols in Immunology. Wiley, New York, 1994. p. 3.11.11-13.11.14.
40. Robbins P.F., Kantor J.A., Salgaller M., Hand P.H., Fernsten P.D., Schlom J. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res. 51:1991;3657-3662.
41. Kantor J., Irvine K., Abrams S., Kaufman H., DiPietro J., Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst. 84:1992;1084-1091.